BWXT Names Robert Duffy as Chief Administrative Officer
(LYNCHBURG, Va. – August 22, 2022) – BWX Technologies, Inc. (NYSE: BWXT) has appointed Robert (Bob) Duffy as senior vice president and chief administrative officer (CAO). In this role, he will have full responsibility for human resources and a number of other business support functions.
BWX Technologies Reports Robust Second Quarter 2022 Results
LYNCHBURG, Va.--(BUSINESS WIRE)-- BWX Technologies, Inc. (NYSE: BWXT) ("BWXT", "we", "us" or the "Company") reported second quarter 2022 revenue of $554 million, a 10% increase compared with $505 million in the second quarter 2021. GAAP net income for the second quarter 2022 was $74.6 million, or $0.82 per diluted share, compared with net income of $59.3 million, or $0.62 per diluted share, in the prior-year period. Non-GAAP(1) net income for the second quarter 2022 was $75.4 million, or $0.82 per diluted share. Adjusted EBITDA(1) for the second quarter 2022 was $114.7 million, a 26% increase compared with $90.8 million in the prior-year period, primarily driven by higher revenue, the timing of certain long lead material production and positive site performance. A reconciliation of non-GAAP(1) results are detailed in Exhibit 1.
BWXT Names Sharon H. Smoot as President of Nuclear Operations Group
(LYNCHBURG, Va. – July 27, 2022) – BWX Technologies, Inc. (NYSE: BWXT) has appointed Sharon H. Smoot as president of BWXT’s Nuclear Operations Group, Inc. (NOG). In this role, she will have full responsibility for NOG’s mission to provide a complete range of nuclear components and services, including the manufacture of nuclear reactor components for U.S. Navy submarines and aircraft carriers and other nuclear and non-nuclear R&D and component production.
BWXT Medical Executes Commercial Agreement with Bayer for Supply of Actinium-225 Based Products
(OTTAWA, ON – June 27, 2022) – BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. has executed a commercial agreement with Bayer AG (Bayer) to supply high-purity Actinium-225 (Ac-225).
BWXT Medical and TRIUMF Execute Agreement for Manufacture of High Purity Ac-225 Based Products
BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. and TRIUMF, Canada’s particle accelerator centre, have executed a licensing and services agreement that strengthens their existing partnership for the production of medical isotopes.
BWXT to Build First Advanced Microreactor in United States
(LYNCHBURG, Va. – June 9, 2022) – BWX Technologies, Inc. (NYSE: BWXT) will build the first advanced nuclear microreactor in the United States under a contract awarded by the U.S. Department of Defense (DoD) Strategic Capabilities Office (SCO). The Project Pele full-scale transportable microreactor prototype will be completed and delivered in 2024 for testing at the Idaho National Laboratory.
BWXT Names Ryan Colvert as Senior Director for Government Relations
(LYNCHBURG, Va. – May 16, 2022) – BWX Technologies, Inc. (NYSE: BWXT) has hired Ryan B. Colvert as a senior director for government relations.